EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer

Sujuan Peng, Hongxiang Huang, Jinhong Chen, Xinjing Ding, Xie Zhu, Yangyang Liu, Li Chen, Zhihui Lu iD

Technology in Cancer Research & Treatment · 2024

DOI: 10.1177/15330338241248573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Sujuan Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, COVID-19, Angiogenesis Inhibitors, Lung Neoplasms. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The 2019 coronavirus disease (COVID-19) pandemic has reshaped oncology practice, but the impact of anti-angiogenic drugs on the severity of COVID-19 in patients with non-small cell lung cancer (NSCLC) remains unclear. Patients and Methods: We carried out a retrospective study involving 166 consecutive patients with NSCLC who were positive for COVID-19, aiming to determine the effects of anti-angiogenic drugs on disease severity, as defined by severe/critical symptoms, intensive care unit (ICU) admission/intubation, and mortality outcomes. Risk factors were identified using univariate and multivariate logistic regression models.

Results

Of the participants, 73 had been administered anti-angiogenic drugs (termed the anti-angiogenic therapy (AT) group), while 93 had not (non-AT group). Comparative analyses showed no significant disparity in the rates of severe/critical symptoms (21.9% vs 35.5%, P = 0.057), ICU admission/intubation (6.8% vs 7.5%, P = 0.867), or death (11.0% vs 9.7%, P = 0.787) between these two groups. However, elevated risk factors for worse outcomes included age ≥ 60 (odds ratio (OR): 2.52, 95% confidence interval (CI): 1.07-5.92), Eastern Cooperative Oncology Group performance status of 2 or higher (OR: 21.29, 95% CI: 4.98-91.01), chronic obstructive pulmonary disease (OR: 7.25, 95% CI: 1.65-31.81), hypertension (OR: 2.98, 95% CI: 1.20-7.39), and use of immunoglobulin (OR: 5.26, 95% CI: 1.06-26.25).

Conclusion

Our data suggests that the use of anti-angiogenic drugs may not exacerbate COVID-19 severity in NSCLC patients, indicating their potential safe application even during the pandemic period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCOVID-19Angiogenesis InhibitorsLung NeoplasmsSARS-CoV-2Severity of Illness IndexHumansMaleFemaleAgedMiddle AgedRetrospective StudiesRisk FactorsIntensive Care Units

Stichwörter der Autor:innen

COVID-19 severityanti-angiogenic drugscoronavirus disease 2019non-small cell lung cancerrisk factors

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.

ORCID-Profile: Zhihui Lu

Zitieren

APA

Peng, S., Huang, H., Chen, J., Ding, X., Zhu, X., Liu, Y., Chen, L., & Lu, Z. (2024). Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241248573

Vancouver

Peng S, Huang H, Chen J, Ding X, Zhu X, Liu Y, et al. Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241248573

BibTeX
@article{Peng2024,
  author = {Peng, Sujuan and Huang, Hongxiang and Chen, Jinhong and Ding, Xinjing and Zhu, Xie and Liu, Yangyang and Chen, Li and Lu, Zhihui},
  title = {Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  doi = {10.1177/15330338241248573}
}
Kostenlos starten →